Influenza A M1 58-66 (HLA-A*02:01) GILGFVFTL
€210.00*
Description
GILGFVFTL is a HLA-A2-restricted epitope from influenza matrix M1 protein.
TechData
| Sequence: | GILGFVFTL |
| Gene: | M |
| Delivery: | 1-3 days |
| C-Terminus: | OH |
| N-Terminus: | H |
| Amount: | 5 mg |
| Counterion: | TFA |
| Protein: | Matrix protein 1 |
| UniProt Id: | P03485 |
| IEDB Id: | https://www.iedb.org/epitope/20354 |
| Species: | Influenza A virus |
| Allele: | HLA-A*02:01, HLA-A2, HLA-A*02:06, HLA-A*02:02, HLA-A*02:03, HLA-C*08:01, HLA-A*68:02, HLA-E*01:03, SLA-3*02:02 |
| Application: | T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response |
| Indication: | Infectious disease |
| Purity: | 95% HPLC-MS |
Documents
References
Dolton, Garry et al. “More tricks with tetramers: a practical guide to staining T cells with peptide-MHC multimers.” Immunology vol. 146,1 (2015): 11-22. doi:10.1111/imm.12499
Kubota, Ryuji et al. "An Altered Peptide Ligand Antagonizes Antigen-Specific T Cells of Patients with Human T Lymphotropic Virus Type I-Associated Neurological Disease". J Immunol 164,10 (2000): 5192–5198. https://doi.org/10.4049/jimmunol.164.10.5192
Di Mario, Giuseppina et al. “Protective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins.” Pathogens and global health vol. 111,2 (2017): 76-82. doi:10.1080/20477724.2016.1275465
Boon, A C M et al. “The magnitude and specificity of influenza A virus-specific cytotoxic T-lymphocyte responses in humans is related to HLA-A and -B phenotype.” Journal of virology vol. 76,2 (2002): 582-90. doi:10.1128/jvi.76.2.582-590.2002
More Influenza peptides